AptaBio Therapeutics Inc. (KOSDAQ:293780)

South Korea flag South Korea · Delayed Price · Currency is KRW
7,000.00
+280.00 (4.17%)
Apr 10, 2026, 3:30 PM KST
Market Cap196.65B -1.9%
Revenue (ttm)3.70B +10.0%
Net Income-16.35B
EPS-607.00
Shares Out28.09M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume58,363
Average Volume102,622
Open6,740.00
Previous Close6,720.00
Day's Range6,740.00 - 7,050.00
52-Week Range6,060.00 - 11,960.00
Beta0.92
RSI47.80
Earnings DateMay 14, 2026

About AptaBio Therapeutics

AptaBio Therapeutics Inc., a biopharmaceutical company, develops platform based drugs for intractable diseases. Its platforms include Oxidative stress modulation platform for developing therapeutic agents for diabetes complications, vascular diseases, neurodegenerative diseases, and intractable cancers by controlling oxidative stress; Cancer-associated fibroblast control platform for developing new anticancer drugs for intractable cancer; and Aptamer-drug conjugate platform for developing intractable anticancer drugs with high unmet medical nee... [Read more]

Sector Healthcare
Founded 2009
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 293780
Full Company Profile

Financial Performance

In 2025, AptaBio Therapeutics's revenue was 3.70 billion, an increase of 10.02% compared to the previous year's 3.36 billion. Losses were -16.35 billion, -44.36% less than in 2024.

Financial Statements